This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Align Technology (ALGN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ALGN Q1 Earnings and Revenues Top Estimates, Stock Up in After-market
by Zacks Equity Research
Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.
Align Technology (ALGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Align Technology (ALGN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 7.58% and 0.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
What to Expect From These 3 MedTech Stocks This Earnings Season?
by Zacks Equity Research
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Align Technology (ALGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALGN Gears Up for Q1 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's first-quarter 2025 results are likely to reflect the strength in its Clear Aligner business.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Align Technology (ALGN) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ICUI Stock Declines Despite Plans for Offsetting Tariff Impacts
by Zacks Equity Research
ICU Medical unveils a strategic plan to offset new U.S. tariffs, aiming to protect margins and stability amid medtech market volatility and global trade shifts.
ALGN or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALGN vs. MMSI: Which Stock Is the Better Value Option?
BD Seeks Potential Buyers for Life Sciences Business Division
by Zacks Equity Research
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
ALGN Stock Gains From the Invisalign System With Mandibular Advancement
by Zacks Equity Research
Align Technology's Invisalign System, featuring mandibular advancement with occlusal blocks, is now commercially available for Class II malocclusion in the growing number of patients.
Is This the Right Time to Hold ALGN Stock in Your Portfolio?
by Zacks Equity Research
Align Technology continues to attract investors' confidence thanks to its share gains in the malocclusion market and strategic deals.
Solventum Partners With SprintRay for Same-Day Dental Restorations
by Zacks Equity Research
SOLV partners with SprintRay to introduce an innovative solution for same-day dental restorations, enhancing efficiency, precision and patient care in digital dentistry.
ALGN Stock to Benefit From the Launch of Align X-ray Insights Solution
by Zacks Equity Research
Align Technologies unveils Align X-ray Insights, an AI-backed CADe solution.
Why Is Align Technology (ALGN) Down 21.2% Since Last Earnings Report?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALGN Stock Gains on Addition of Upgrades to the iTero Lumina Solutions
by Zacks Equity Research
Align Technology adds restorative capabilities to the iTero Lumina Solutions - the iTero Lumina intraoral scanner and the iTero Lumina Pro dental imaging system.
ALGN Stock Gains on the Launch of Invisalign Palatal Expander in Turkey
by Zacks Equity Research
Align Technology commercially launches its Invisalign Palatal Expander System in Turkey after approval from TMMDA.
ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports fourth-quarter 2024 revenue growth. This can be mostly attributed to the robust performance of the Imaging Systems & CAD/CAM Services business segment.
Align Technology (ALGN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Align Technology (ALGN) Beats Q4 Earnings Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 0.41% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?